ID   ARSB_HUMAN              Reviewed;         533 AA.
AC   P15848; B2RC20; Q8N322; Q9UDI9;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   10-MAY-2017, entry version 178.
DE   RecName: Full=Arylsulfatase B;
DE            Short=ASB;
DE            EC=3.1.6.12;
DE   AltName: Full=N-acetylgalactosamine-4-sulfatase;
DE            Short=G4S;
DE   Flags: Precursor;
GN   Name=ARSB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF
RP   103-119; 135-158; 161-168; 286-295; 319-337; 379-387; 389-410;
RP   440-450; 490-501; 508-520 AND 525-533.
RC   TISSUE=Placenta, and Testis;
RX   PubMed=2303452;
RA   Peters C., Schmidt B., Rommerskirch W., Rupp K., Zuehlsdorf M.,
RA   Vingron M., Meyer H.E., Pohlmann R., von Figura K.;
RT   "Phylogenetic conservation of arylsulfatases. cDNA cloning and
RT   expression of human arylsulfatase B.";
RL   J. Biol. Chem. 265:3374-3381(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1968043; DOI=10.1016/0888-7543(90)90460-C;
RA   Schuchman E.H., Jackson C.E., Desnick R.J.;
RT   "Human arylsulfatase B: MOPAC cloning, nucleotide sequence of a full-
RT   length cDNA, and regions of amino acid identity with arylsulfatases A
RT   and C.";
RL   Genomics 6:149-158(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT MET-358.
RX   PubMed=7687847;
RA   Modaressi S., Rupp K., von Figura K., Peters C.;
RT   "Structure of the human arylsulfatase B gene.";
RL   Biol. Chem. Hoppe-Seyler 374:327-335(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   MET-358.
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-104.
RX   PubMed=1930244;
RA   Litjens T., Morris C.P., Gibson G.J., Beckmann K.R., Hopwood J.J.;
RT   "Human N-acetylgalactosamine-4-sulphatase: protein maturation and
RT   isolation of genomic clones.";
RL   Biochem. Int. 24:209-215(1991).
RN   [9]
RP   PROTEIN SEQUENCE OF 41-55; 424-454 AND 466-483.
RC   TISSUE=Placenta;
RX   PubMed=1390929; DOI=10.1016/0167-4838(92)90051-E;
RA   Kobayashi T., Honke K., Jin T., Gasa S., Miyazaki T., Makita A.;
RT   "Components and proteolytic processing sites of arylsulfatase B from
RT   human placenta.";
RL   Biochim. Biophys. Acta 1159:243-247(1992).
RN   [10]
RP   OXOALANINE AT CYS-91, IDENTIFICATION BY MASS SPECTROMETRY, AND ABSENCE
RP   OF OXOALANINE IN MSD.
RX   PubMed=7628016; DOI=10.1016/0092-8674(95)90314-3;
RA   Schmidt B., Selmer T., Ingendoh A., von Figura K.;
RT   "A novel amino acid modification in sulfatases that is defective in
RT   multiple sulfatase deficiency.";
RL   Cell 82:271-278(1995).
RN   [11]
RP   INVOLVEMENT IN MSD.
RX   PubMed=15146462; DOI=10.1002/humu.20040;
RA   Cosma M.P., Pepe S., Parenti G., Settembre C., Annunziata I.,
RA   Wade-Martins R., Domenico C.D., Natale P.D., Mankad A., Cox B.,
RA   Uziel G., Mancini G.M., Zammarchi E., Donati M.A., Kleijer W.J.,
RA   Filocamo M., Carrozzo R., Carella M., Ballabio A.;
RT   "Molecular and functional analysis of SUMF1 mutations in multiple
RT   sulfatase deficiency.";
RL   Hum. Mutat. 23:576-581(2004).
RN   [12]
RP   FUNCTION.
RX   PubMed=19306108; DOI=10.1007/s10585-009-9253-z;
RA   Bhattacharyya S., Tobacman J.K.;
RT   "Arylsulfatase B regulates colonic epithelial cell migration by
RT   effects on MMP9 expression and RhoA activation.";
RL   Clin. Exp. Metastasis 26:535-545(2009).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-366.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS).
RX   PubMed=9032078; DOI=10.1016/S0969-2126(97)00185-8;
RA   Bond C.S., Clements P.R., Ashby S.J., Collyer C.A., Harrop S.J.,
RA   Hopwood J.J., Guss J.M.;
RT   "Structure of a human lysosomal sulfatase.";
RL   Structure 5:277-289(1997).
RN   [16]
RP   VARIANT MPS6 VAL-137, AND VARIANT MET-376.
RX   PubMed=1718978;
RA   Wicker G., Prill V., Brooks D.A., Gibson G.J., Hopwood J.J.,
RA   von Figura K., Peters C.;
RT   "Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). An intermediate
RT   clinical phenotype caused by substitution of valine for glycine at
RT   position 137 of arylsulfatase B.";
RL   J. Biol. Chem. 266:21386-21391(1991).
RN   [17]
RP   VARIANTS MPS6 ARG-117; PRO-236 AND TYR-405.
RX   PubMed=1550123;
RA   Jin W.-D., Jackson C.E., Desnick R.J., Schuchman E.H.;
RT   "Mucopolysaccharidosis type VI: identification of three mutations in
RT   the arylsulfatase B gene of patients with the severe and mild
RT   phenotypes provides molecular evidence for genetic heterogeneity.";
RL   Am. J. Hum. Genet. 50:795-800(1992).
RN   [18]
RP   VARIANTS MPS6 ARG-144; ARG-192; PRO-321 AND TYR-521, AND
RP   CHARACTERIZATION OF VARIANTS MPS6.
RX   PubMed=8116615;
RA   Isbrandt D., Arlt G., Brooks D.A., Hopwood J.J., von Figura K.,
RA   Peters C.;
RT   "Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): six unique
RT   arylsulfatase B gene alleles causing variable disease phenotypes.";
RL   Am. J. Hum. Genet. 54:454-463(1994).
RN   [19]
RP   VARIANTS MPS6 TRP-152 AND GLN-160.
RX   PubMed=8125475; DOI=10.1007/BF00212019;
RA   Voskoboeva E., Isbrandt D., von Figura K., Krasnopolskaya X.,
RA   Peters C.;
RT   "Four novel mutant alleles of the arylsulfatase B gene in two patients
RT   with intermediate form of mucopolysaccharidosis VI (Maroteaux-Lamy
RT   syndrome).";
RL   Hum. Genet. 93:259-264(1994).
RN   [20]
RP   VARIANTS MPS6 ILE-142; ARG-146; LEU-146 AND SER-146.
RX   PubMed=8541342; DOI=10.1016/0925-4439(95)00070-4;
RA   Simonaro C.M., Schuchman E.H.;
RT   "N-acetylgalactosamine-4-sulfatase: identification of four new
RT   mutations within the conserved sulfatase region causing
RT   mucopolysaccharidosis type VI.";
RL   Biochim. Biophys. Acta 1272:129-132(1995).
RN   [21]
RP   VARIANTS MPS6 MET-92; GLN-95; CYS-210; PRO-393 AND PRO-498.
RX   PubMed=8651289;
RA   Litjens T., Brooks D.A., Peters C., Gibson G.J., Hopwood J.J.;
RT   "Identification, expression, and biochemical characterization of N-
RT   acetylgalactosamine-4-sulfatase mutations and relationship with
RT   clinical phenotype in MPS6 patients.";
RL   Am. J. Hum. Genet. 58:1127-1134(1996).
RN   [22]
RP   VARIANT MPS-IV ARG-302.
RX   PubMed=10206678;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:5<410::AID-HUMU9>3.0.CO;2-Q;
RA   Villani G.R.D., Balzano N., Di Natale P.;
RT   "Two novel mutations of the arylsulfatase B gene in two Italian
RT   patients with severe form of mucopolysaccharidosis.";
RL   Hum. Mutat. 11:410-410(1998).
RN   [23]
RP   VARIANT MET-358.
RX   PubMed=9582121; DOI=10.1126/science.280.5366.1077;
RA   Wang D.G., Fan J.-B., Siao C.-J., Berno A., Young P., Sapolsky R.,
RA   Ghandour G., Perkins N., Winchester E., Spencer J., Kruglyak L.,
RA   Stein L., Hsie L., Topaloglou T., Hubbell E., Robinson E.,
RA   Mittmann M., Morris M.S., Shen N., Kilburn D., Rioux J., Nusbaum C.,
RA   Rozen S., Hudson T.J., Lipshutz R., Chee M., Lander E.S.;
RT   "Large-scale identification, mapping, and genotyping of single-
RT   nucleotide polymorphisms in the human genome.";
RL   Science 280:1077-1082(1998).
RN   [24]
RP   VARIANTS MPS6 PHE-65; HIS-116; GLN-315 AND ARG-531, AND VARIANT
RP   MET-358.
RX   PubMed=10036316; DOI=10.1016/S0925-4439(98)00099-4;
RA   Villani G.R.D., Balzano N., Vitale D., Saviano M., Pavone V.,
RA   Di Natale P.;
RT   "Maroteaux-Lamy syndrome: five novel mutations and their structural
RT   localization.";
RL   Biochim. Biophys. Acta 1453:185-192(1999).
RN   [25]
RP   VARIANTS MPS6 ARG-192 AND ARG-239.
RX   PubMed=10738004;
RX   DOI=10.1002/(SICI)1098-1004(200004)15:4<389::AID-HUMU31>3.0.CO;2-0;
RA   Wu J.-Y., Yang C.-F., Lee C.-C., Chang J.-G., Tsai F.-J.;
RT   "A novel mutation (Q239R) identified in a Taiwan Chinese patient with
RT   type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome).";
RL   Hum. Mutat. 15:389-390(2000).
RN   [26]
RP   VARIANTS MPS6 ARG-192; ARG-239 AND LEU-399, AND VARIANT MET-358.
RX   PubMed=11802522;
RA   Yang C.-F., Wu J.-Y., Lin S.-P., Tsai F.-J.;
RT   "Mucopolysaccharidosis type VI: report of two Taiwanese patients and
RT   identification of one novel mutation.";
RL   J. Formos. Med. Assoc. 100:820-823(2001).
RN   [27]
RP   VARIANTS MPS6 TYR-86 DEL; CYS-210; PRO-236; CYS-312; GLN-315; PRO-321;
RP   ASN-384 AND GLY-484, VARIANTS MET-358 AND MET-376, AND
RP   CHARACTERIZATION OF VARIANTS MPS6 TYR-86 DEL AND CYS-312.
RX   PubMed=14974081; DOI=10.1002/humu.10313;
RA   Karageorgos L., Harmatz P., Simon J., Pollard A., Clements P.R.,
RA   Brooks D.A., Hopwood J.J.;
RT   "Mutational analysis of mucopolysaccharidosis type VI patients
RT   undergoing a trial of enzyme replacement therapy.";
RL   Hum. Mutat. 23:229-233(2004).
CC   -!- FUNCTION: Removes sulfate groups from chondroitin-4-sulfate (C4S)
CC       and regulates its degradation (PubMed:19306108). Involved in the
CC       regulation of cell adhesion, cell migration and invasion in
CC       colonic epithelium (PubMed:19306108). In the central nervous
CC       system, is a regulator of neurite outgrowth and neuronal
CC       plasticity, acting through the control of sulfate
CC       glycosaminoglycans and neurocan levels (By similarity).
CC       {ECO:0000250|UniProtKB:P50430, ECO:0000269|PubMed:19306108}.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of the 4-sulfate groups of the N-
CC       acetyl-D-galactosamine 4-sulfate units of chondroitin sulfate and
CC       dermatan sulfate.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC       Note=Binds 1 Ca(2+) ion per subunit.;
CC   -!- ENZYME REGULATION: Inhibited by ethanol (By similarity).
CC       {ECO:0000250|UniProtKB:P50430}.
CC   -!- SUBUNIT: Monomer.
CC   -!- SUBCELLULAR LOCATION: Lysosome {ECO:0000250|UniProtKB:P50429}.
CC       Cell surface {ECO:0000250|UniProtKB:P50429}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P15848-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P15848-2; Sequence=VSP_042721;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: The conversion to 3-oxoalanine (also known as C-
CC       formylglycine, FGly), of a serine or cysteine residue in
CC       prokaryotes and of a cysteine residue in eukaryotes, is critical
CC       for catalytic activity. This post-translational modification is
CC       severely defective in multiple sulfatase deficiency (MSD).
CC       {ECO:0000269|PubMed:7628016}.
CC   -!- DISEASE: Mucopolysaccharidosis 6 (MPS6) [MIM:253200]: An autosomal
CC       recessive lysosomal storage disease characterized by intracellular
CC       accumulation of dermatan sulfate. Clinical features can include
CC       abnormal growth, short stature, stiff joints, skeletal
CC       malformations, corneal clouding, hepatosplenomegaly, and cardiac
CC       abnormalities. A wide variation in clinical severity is observed.
CC       {ECO:0000269|PubMed:10036316, ECO:0000269|PubMed:10738004,
CC       ECO:0000269|PubMed:11802522, ECO:0000269|PubMed:14974081,
CC       ECO:0000269|PubMed:1550123, ECO:0000269|PubMed:1718978,
CC       ECO:0000269|PubMed:8116615, ECO:0000269|PubMed:8125475,
CC       ECO:0000269|PubMed:8541342, ECO:0000269|PubMed:8651289}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Multiple sulfatase deficiency (MSD) [MIM:272200]: A
CC       clinically and biochemically heterogeneous disorder caused by the
CC       simultaneous impairment of all sulfatases, due to defective post-
CC       translational modification and activation. It combines features of
CC       individual sulfatase deficiencies such as metachromatic
CC       leukodystrophy, mucopolysaccharidosis, chondrodysplasia punctata,
CC       hydrocephalus, ichthyosis, neurologic deterioration and
CC       developmental delay. {ECO:0000269|PubMed:15146462}. Note=The
CC       protein represented in this entry is involved in disease
CC       pathogenesis. Arylsulfatase B activity is impaired in multiple
CC       sulfatase deficiency due to mutations in SUMF1. SUMF1 mutations
CC       result in defective post-translational modification of ARSB at
CC       residue Cys-91 that is not converted to 3-oxoalanine.
CC   -!- SIMILARITY: Belongs to the sulfatase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J05225; AAA51784.1; -; mRNA.
DR   EMBL; M32373; AAA51779.1; -; mRNA.
DR   EMBL; X72735; CAA51272.1; -; Genomic_DNA.
DR   EMBL; X72736; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72737; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72738; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72739; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72740; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72741; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72742; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; AK314903; BAG37417.1; -; mRNA.
DR   EMBL; AC020937; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC025755; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC099485; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC114963; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471084; EAW95822.1; -; Genomic_DNA.
DR   EMBL; BC029051; AAH29051.1; -; mRNA.
DR   EMBL; S57777; AAB19988.1; -; Genomic_DNA.
DR   CCDS; CCDS4043.1; -. [P15848-1]
DR   CCDS; CCDS43334.1; -. [P15848-2]
DR   PIR; S35990; KJHUAB.
DR   RefSeq; NP_000037.2; NM_000046.3. [P15848-1]
DR   RefSeq; NP_942002.1; NM_198709.2. [P15848-2]
DR   RefSeq; XP_011541692.1; XM_011543390.1. [P15848-1]
DR   UniGene; Hs.149103; -.
DR   UniGene; Hs.604199; -.
DR   PDB; 1FSU; X-ray; 2.50 A; A=42-533.
DR   PDBsum; 1FSU; -.
DR   ProteinModelPortal; P15848; -.
DR   SMR; P15848; -.
DR   BioGrid; 106904; 11.
DR   IntAct; P15848; 2.
DR   STRING; 9606.ENSP00000264914; -.
DR   ChEMBL; CHEMBL2399; -.
DR   iPTMnet; P15848; -.
DR   PhosphoSitePlus; P15848; -.
DR   BioMuta; ARSB; -.
DR   EPD; P15848; -.
DR   MaxQB; P15848; -.
DR   PaxDb; P15848; -.
DR   PeptideAtlas; P15848; -.
DR   PRIDE; P15848; -.
DR   Ensembl; ENST00000264914; ENSP00000264914; ENSG00000113273. [P15848-1]
DR   Ensembl; ENST00000396151; ENSP00000379455; ENSG00000113273. [P15848-2]
DR   Ensembl; ENST00000565165; ENSP00000456339; ENSG00000113273. [P15848-2]
DR   GeneID; 411; -.
DR   KEGG; hsa:411; -.
DR   UCSC; uc003kfq.5; human. [P15848-1]
DR   CTD; 411; -.
DR   DisGeNET; 411; -.
DR   GeneCards; ARSB; -.
DR   HGNC; HGNC:714; ARSB.
DR   HPA; HPA037770; -.
DR   HPA; HPA037771; -.
DR   MalaCards; ARSB; -.
DR   MIM; 253200; phenotype.
DR   MIM; 272200; phenotype.
DR   MIM; 611542; gene.
DR   neXtProt; NX_P15848; -.
DR   OpenTargets; ENSG00000113273; -.
DR   Orphanet; 276212; Mucopolysaccharidosis type 6, rapidly progressing.
DR   Orphanet; 276223; Mucopolysaccharidosis type 6, slowly progressing.
DR   PharmGKB; PA25006; -.
DR   eggNOG; KOG3867; Eukaryota.
DR   eggNOG; COG3119; LUCA.
DR   GeneTree; ENSGT00760000119062; -.
DR   HOGENOM; HOG000135354; -.
DR   HOVERGEN; HBG004282; -.
DR   InParanoid; P15848; -.
DR   KO; K01135; -.
DR   OMA; QDPEERH; -.
DR   OrthoDB; EOG091G06C3; -.
DR   PhylomeDB; P15848; -.
DR   TreeFam; TF314186; -.
DR   BioCyc; MetaCyc:HS03665-MONOMER; -.
DR   BRENDA; 3.1.6.12; 2681.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   Reactome; R-HSA-1663150; The activation of arylsulfatases.
DR   Reactome; R-HSA-2024101; CS/DS degradation.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SABIO-RK; P15848; -.
DR   ChiTaRS; ARSB; human.
DR   EvolutionaryTrace; P15848; -.
DR   GenomeRNAi; 411; -.
DR   PRO; PR:P15848; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000113273; -.
DR   CleanEx; HS_ARSB; -.
DR   ExpressionAtlas; P15848; baseline and differential.
DR   Genevisible; P15848; HS.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; TAS:ProtInc.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0004065; F:arylsulfatase activity; TAS:ProtInc.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003943; F:N-acetylgalactosamine-4-sulfatase activity; IDA:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IEA:Ensembl.
DR   GO; GO:0007417; P:central nervous system development; IEA:Ensembl.
DR   GO; GO:0030207; P:chondroitin sulfate catabolic process; TAS:Reactome.
DR   GO; GO:0061580; P:colon epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0007041; P:lysosomal transport; TAS:ProtInc.
DR   GO; GO:0007040; P:lysosome organization; TAS:ProtInc.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0010632; P:regulation of epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0051597; P:response to methylmercury; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0009268; P:response to pH; IEA:Ensembl.
DR   Gene3D; 3.40.720.10; -; 1.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   InterPro; IPR024607; Sulfatase_CS.
DR   InterPro; IPR000917; Sulfatase_N.
DR   Pfam; PF00884; Sulfatase; 1.
DR   SUPFAM; SSF53649; SSF53649; 1.
DR   PROSITE; PS00523; SULFATASE_1; 1.
DR   PROSITE; PS00149; SULFATASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Hydrolase; Ichthyosis; Leukodystrophy; Lysosome;
KW   Metachromatic leukodystrophy; Metal-binding; Mucopolysaccharidosis;
KW   Polymorphism; Reference proteome; Signal.
FT   SIGNAL        1     36       Or 38. {ECO:0000255}.
FT   CHAIN        37    533       Arylsulfatase B.
FT                                /FTId=PRO_0000033421.
FT   ACT_SITE    147    147
FT   METAL        53     53       Calcium.
FT   METAL        54     54       Calcium.
FT   METAL        91     91       Calcium; via 3-oxoalanine.
FT                                {ECO:0000269|PubMed:7628016}.
FT   METAL       300    300       Calcium.
FT   METAL       301    301       Calcium.
FT   BINDING     145    145       Substrate. {ECO:0000250}.
FT   BINDING     242    242       Substrate. {ECO:0000250}.
FT   BINDING     318    318       Substrate. {ECO:0000250}.
FT   MOD_RES      91     91       3-oxoalanine (Cys).
FT                                {ECO:0000269|PubMed:7628016}.
FT   CARBOHYD    188    188       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    279    279       N-linked (GlcNAc...) asparagine.
FT   CARBOHYD    291    291       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000305}.
FT   CARBOHYD    366    366       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    426    426       N-linked (GlcNAc...) asparagine.
FT   CARBOHYD    458    458       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID    117    521
FT   DISULFID    121    155
FT   DISULFID    181    192
FT   DISULFID    405    447
FT   VAR_SEQ     405    533       CPRNSMAPAKDDSSLPEYSAFNTSVHAAIRHGNWKLLTGYP
FT                                GCGYWFPPPSQYNVSEIPSSDPPTKTLWLFDIDRDPEERHD
FT                                LSREYPHIVTKLLSRLQFYHKHSVPVYFPAQDPRCDPKATG
FT                                VWGPWM -> YWPECSLLL (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_042721.
FT   VARIANT      65     65       S -> F (in MPS6; intermediate form).
FT                                {ECO:0000269|PubMed:10036316}.
FT                                /FTId=VAR_019017.
FT   VARIANT      86     86       Missing (in MPS6; severe form; low
FT                                protein levels and activity).
FT                                {ECO:0000269|PubMed:14974081}.
FT                                /FTId=VAR_019018.
FT   VARIANT      92     92       T -> M (in MPS6; mild form;
FT                                dbSNP:rs751010538).
FT                                {ECO:0000269|PubMed:8651289}.
FT                                /FTId=VAR_007294.
FT   VARIANT      95     95       R -> Q (in MPS6; mild/severe form;
FT                                dbSNP:rs118203942).
FT                                {ECO:0000269|PubMed:8651289}.
FT                                /FTId=VAR_007295.
FT   VARIANT     116    116       P -> H (in MPS6; severe form;
FT                                dbSNP:rs775780931).
FT                                {ECO:0000269|PubMed:10036316}.
FT                                /FTId=VAR_019019.
FT   VARIANT     117    117       C -> R (in MPS6; severe form;
FT                                dbSNP:rs118203939).
FT                                {ECO:0000269|PubMed:1550123}.
FT                                /FTId=VAR_007296.
FT   VARIANT     137    137       G -> V (in MPS6; intermediate form;
FT                                dbSNP:rs118203938).
FT                                {ECO:0000269|PubMed:1718978}.
FT                                /FTId=VAR_007297.
FT   VARIANT     142    142       M -> I (in MPS6).
FT                                {ECO:0000269|PubMed:8541342}.
FT                                /FTId=VAR_019020.
FT   VARIANT     144    144       G -> R (in MPS6; severe form; severe
FT                                reduction of activity;
FT                                dbSNP:rs746206847).
FT                                {ECO:0000269|PubMed:8116615}.
FT                                /FTId=VAR_019021.
FT   VARIANT     146    146       W -> L (in MPS6).
FT                                {ECO:0000269|PubMed:8541342}.
FT                                /FTId=VAR_019022.
FT   VARIANT     146    146       W -> R (in MPS6).
FT                                {ECO:0000269|PubMed:8541342}.
FT                                /FTId=VAR_019023.
FT   VARIANT     146    146       W -> S (in MPS6).
FT                                {ECO:0000269|PubMed:8541342}.
FT                                /FTId=VAR_019024.
FT   VARIANT     152    152       R -> W (in MPS6; intermediate form).
FT                                {ECO:0000269|PubMed:8125475}.
FT                                /FTId=VAR_007298.
FT   VARIANT     160    160       R -> Q (in MPS6; intermediate form).
FT                                {ECO:0000269|PubMed:8125475}.
FT                                /FTId=VAR_007299.
FT   VARIANT     192    192       C -> R (in MPS6; mild form; severe
FT                                reduction of activity).
FT                                {ECO:0000269|PubMed:10738004,
FT                                ECO:0000269|PubMed:11802522,
FT                                ECO:0000269|PubMed:8116615}.
FT                                /FTId=VAR_019025.
FT   VARIANT     210    210       Y -> C (in MPS6; mild/intermediate;
FT                                dbSNP:rs118203943).
FT                                {ECO:0000269|PubMed:14974081,
FT                                ECO:0000269|PubMed:8651289}.
FT                                /FTId=VAR_007300.
FT   VARIANT     236    236       L -> P (in MPS6; mild form;
FT                                dbSNP:rs118203940).
FT                                {ECO:0000269|PubMed:14974081,
FT                                ECO:0000269|PubMed:1550123}.
FT                                /FTId=VAR_007301.
FT   VARIANT     239    239       Q -> R (in MPS6).
FT                                {ECO:0000269|PubMed:10738004,
FT                                ECO:0000269|PubMed:11802522}.
FT                                /FTId=VAR_019026.
FT   VARIANT     302    302       G -> R (in MPS6; severe form;
FT                                dbSNP:rs779378413).
FT                                {ECO:0000269|PubMed:10206678}.
FT                                /FTId=VAR_007302.
FT   VARIANT     312    312       W -> C (in MPS6; severe form; low protein
FT                                levels and activity).
FT                                {ECO:0000269|PubMed:14974081}.
FT                                /FTId=VAR_019027.
FT   VARIANT     315    315       R -> Q (in MPS6; intermediate form;
FT                                dbSNP:rs727503809).
FT                                {ECO:0000269|PubMed:10036316,
FT                                ECO:0000269|PubMed:14974081}.
FT                                /FTId=VAR_019028.
FT   VARIANT     321    321       L -> P (in MPS6; intermediate form;
FT                                severe reduction of activity).
FT                                {ECO:0000269|PubMed:14974081,
FT                                ECO:0000269|PubMed:8116615}.
FT                                /FTId=VAR_019029.
FT   VARIANT     358    358       V -> L (in dbSNP:rs1065757).
FT                                /FTId=VAR_061883.
FT   VARIANT     358    358       V -> M (in dbSNP:rs1065757).
FT                                {ECO:0000269|PubMed:10036316,
FT                                ECO:0000269|PubMed:11802522,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:14974081,
FT                                ECO:0000269|PubMed:7687847,
FT                                ECO:0000269|PubMed:9582121}.
FT                                /FTId=VAR_016061.
FT   VARIANT     376    376       V -> M (in dbSNP:rs17220759).
FT                                {ECO:0000269|PubMed:14974081,
FT                                ECO:0000269|PubMed:1718978}.
FT                                /FTId=VAR_007303.
FT   VARIANT     384    384       S -> N (in MPS6; dbSNP:rs25414).
FT                                {ECO:0000269|PubMed:14974081}.
FT                                /FTId=VAR_019030.
FT   VARIANT     393    393       H -> P (in MPS6; mild/severe form;
FT                                dbSNP:rs118203944).
FT                                {ECO:0000269|PubMed:8651289}.
FT                                /FTId=VAR_007304.
FT   VARIANT     399    399       F -> L (in MPS6; dbSNP:rs200793396).
FT                                {ECO:0000269|PubMed:11802522}.
FT                                /FTId=VAR_019031.
FT   VARIANT     405    405       C -> Y (in MPS6; mild form;
FT                                dbSNP:rs118203941).
FT                                {ECO:0000269|PubMed:1550123}.
FT                                /FTId=VAR_007305.
FT   VARIANT     484    484       R -> G (in MPS6; dbSNP:rs201101343).
FT                                {ECO:0000269|PubMed:14974081}.
FT                                /FTId=VAR_019032.
FT   VARIANT     498    498       L -> P (in MPS6; mild/severe form;
FT                                dbSNP:rs774358117).
FT                                {ECO:0000269|PubMed:8651289}.
FT                                /FTId=VAR_007306.
FT   VARIANT     521    521       C -> Y (in MPS6; severe form; severe
FT                                reduction of activity).
FT                                {ECO:0000269|PubMed:8116615}.
FT                                /FTId=VAR_019033.
FT   VARIANT     531    531       P -> R (in MPS6; mild form).
FT                                {ECO:0000269|PubMed:10036316}.
FT                                /FTId=VAR_019034.
FT   CONFLICT    153    153       K -> F (in Ref. 1; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    408    410       NSM -> SPC (in Ref. 1; AA sequence).
FT                                {ECO:0000305}.
FT   STRAND       46     54       {ECO:0000244|PDB:1FSU}.
FT   HELIX        61     63       {ECO:0000244|PDB:1FSU}.
FT   HELIX        70     77       {ECO:0000244|PDB:1FSU}.
FT   STRAND       79     82       {ECO:0000244|PDB:1FSU}.
FT   HELIX        91    100       {ECO:0000244|PDB:1FSU}.
FT   HELIX       104    107       {ECO:0000244|PDB:1FSU}.
FT   HELIX       129    135       {ECO:0000244|PDB:1FSU}.
FT   STRAND      139    144       {ECO:0000244|PDB:1FSU}.
FT   HELIX       153    155       {ECO:0000244|PDB:1FSU}.
FT   HELIX       157    159       {ECO:0000244|PDB:1FSU}.
FT   STRAND      163    167       {ECO:0000244|PDB:1FSU}.
FT   STRAND      169    171       {ECO:0000244|PDB:1FSU}.
FT   TURN        175    177       {ECO:0000244|PDB:1FSU}.
FT   STRAND      179    184       {ECO:0000244|PDB:1FSU}.
FT   TURN        185    188       {ECO:0000244|PDB:1FSU}.
FT   STRAND      189    194       {ECO:0000244|PDB:1FSU}.
FT   HELIX       211    224       {ECO:0000244|PDB:1FSU}.
FT   STRAND      232    237       {ECO:0000244|PDB:1FSU}.
FT   STRAND      242    244       {ECO:0000244|PDB:1FSU}.
FT   HELIX       249    251       {ECO:0000244|PDB:1FSU}.
FT   HELIX       253    255       {ECO:0000244|PDB:1FSU}.
FT   HELIX       261    286       {ECO:0000244|PDB:1FSU}.
FT   HELIX       290    292       {ECO:0000244|PDB:1FSU}.
FT   STRAND      293    301       {ECO:0000244|PDB:1FSU}.
FT   HELIX       305    307       {ECO:0000244|PDB:1FSU}.
FT   STRAND      320    322       {ECO:0000244|PDB:1FSU}.
FT   HELIX       323    326       {ECO:0000244|PDB:1FSU}.
FT   STRAND      330    333       {ECO:0000244|PDB:1FSU}.
FT   STRAND      341    344       {ECO:0000244|PDB:1FSU}.
FT   HELIX       350    352       {ECO:0000244|PDB:1FSU}.
FT   HELIX       353    360       {ECO:0000244|PDB:1FSU}.
FT   HELIX       377    382       {ECO:0000244|PDB:1FSU}.
FT   STRAND      390    396       {ECO:0000244|PDB:1FSU}.
FT   STRAND      429    435       {ECO:0000244|PDB:1FSU}.
FT   STRAND      438    443       {ECO:0000244|PDB:1FSU}.
FT   TURN        454    456       {ECO:0000244|PDB:1FSU}.
FT   STRAND      472    476       {ECO:0000244|PDB:1FSU}.
FT   TURN        477    479       {ECO:0000244|PDB:1FSU}.
FT   TURN        488    490       {ECO:0000244|PDB:1FSU}.
FT   HELIX       492    507       {ECO:0000244|PDB:1FSU}.
FT   HELIX       519    521       {ECO:0000244|PDB:1FSU}.
FT   TURN        524    526       {ECO:0000244|PDB:1FSU}.
SQ   SEQUENCE   533 AA;  59687 MW;  5983FB6911C4789A CRC64;
     MGPRGAASLP RGPGPRRLLL PVVLPLLLLL LLAPPGSGAG ASRPPHLVFL LADDLGWNDV
     GFHGSRIRTP HLDALAAGGV LLDNYYTQPL CTPSRSQLLT GRYQIRTGLQ HQIIWPCQPS
     CVPLDEKLLP QLLKEAGYTT HMVGKWHLGM YRKECLPTRR GFDTYFGYLL GSEDYYSHER
     CTLIDALNVT RCALDFRDGE EVATGYKNMY STNIFTKRAI ALITNHPPEK PLFLYLALQS
     VHEPLQVPEE YLKPYDFIQD KNRHHYAGMV SLMDEAVGNV TAALKSSGLW NNTVFIFSTD
     NGGQTLAGGN NWPLRGRKWS LWEGGVRGVG FVASPLLKQK GVKNRELIHI SDWLPTLVKL
     ARGHTNGTKP LDGFDVWKTI SEGSPSPRIE LLHNIDPNFV DSSPCPRNSM APAKDDSSLP
     EYSAFNTSVH AAIRHGNWKL LTGYPGCGYW FPPPSQYNVS EIPSSDPPTK TLWLFDIDRD
     PEERHDLSRE YPHIVTKLLS RLQFYHKHSV PVYFPAQDPR CDPKATGVWG PWM
//
